nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2018-22-2-59-67nefr-352Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESЛЕКАРСТВЕННАЯ ТЕРАПИЯ БОЛЬНЫХ С ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК: ЕСТЬ ЛИ В НЕЙ МЕСТО ДЛЯ ДВОЙНОГО ИНГИБИТОРА НЕПРИЛИЗИНА И АТ1-АНГИОТЕНЗИНОВЫХ РЕЦЕПТОРОВ LCZ696 (САКУБИТРИЛ/ВАЛСАРТАН)?DRUG THERAPY FOR PATIENTS WITH CHRONIC KIDNEY DISEASE: IS THERE A PLACE FOR DOUBLE NEPRILYSIN AND AT1-ANGIOTENSIN RECEPTOR INHIBITOR LCZ696 (SACUBITRIL/VALSARTAN)?КузьминО. Б.KuzminO. B.

Кузьмин Олег Борисович, профессор, кафедра фармакологии. 

460000, Россия, г.Оренбург, Парковый пр., д. 7. 

Oleg B Kuzmin, MD, PhD, DMedSci, Prof.,  Department of Pharmacology 

460000 Russia, Orenburg, Park st., 7.

kuzmin.orgma@mail.ruЖежаВ. В.ZhezhaV. V.

46000, г.Оренбург, Парковый пр., д. 7.

460000 Russia, Orenburg, Park st., 7.

zhezha56@mail.ruБелянинВ. В.BelayninV. V.

46000, г.Оренбург, Парковый пр., д. 7.

Vitaly V. Belyanin,  Department of Pharmacology 

460000 Russia, Orenburg, Park st., 7.

Vitbelya@yandex.ruЛандарьЛ. Н.LandarL. N.

Ландарь Лариса Николаевна, кандидат медицинских наук, кафедра фармакологии

46000, г.Оренбург, Парковый пр., д. 7.

Larisa N. Landar,  Department of Pharmacology 

460000 Russia, Orenburg, Park st., 7.

Landar@mail.ruОренбургский государственный медицинский университетРоссияOrenburg State Medical UniversityRussian Federation2018120220202225967Copyright © Кузьмин О.Б., Жежа В.В., Белянин В.В., Ландарь Л.Н., 20202020Кузьмин О.Б., Жежа В.В., Белянин В.В., Ландарь Л.Н.Kuzmin O.B., Zhezha V.V., Belaynin V.V., Landar L.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/352

В обзоре представлены данные об участии системы циркулирующих и тканевых почечных натрийуретических пептидов в механизме, поддерживающем водно-солевой гомеостаз и защищающем почки от повреждения различной этиологии, а также результаты, полученные при оценке клинической эффективности и безопасности применения нового препарата из группы ингибиторов вазопептидаз LCZ696 (сакубитрил/валсартан) у пациентов с хронической болезнью почек. 

хроническая болезнь почекнатрийуретические пептидыLCZ696 (сакубитрил/валсартан)chronic kidney diseasenatriuretic peptidesLCZ696 (sacubitril/valsartan)ReferencesEgido J, Rojas-Rivera J, Vas S et al. Atrasentan for the treatment of diabetic nephropathy. Expert Opin Investig Drugs 2017; 26 (6): 741–750 doi: 10.1080/13543784.2017.1325872Egido J, Rojas-Rivera J, Vas S et al. Atrasentan for the treatment of diabetic nephropathy. Expert Opin Investig Drugs 2017; 26 (6): 741–750 doi: 10.1080/13543784.2017.1325872Кузьмин ОБ, Жежа ВВ, Ландарь ЛН. Нефропротективные свойства дигидропиридиновых блокаторов Са2+-каналов. Обзоры по клинической фармакологии и лекарственной терапии 2010; 8 (1): 6–12 [Kuz’min OB, Zhezha VV, Landar’ LN. Nefroprotektivnye svojstva digidropipridinovyh blokatorov Ca2+kanalov. Obsory po klinicheskoj farmacologii i lekarstvennoj terapii 2010; 8 (1): 6–12]Кузьмин ОБ, Жежа ВВ, Ландарь ЛН. Нефропротективные свойства дигидропиридиновых блокаторов Са2+-каналов. Обзоры по клинической фармакологии и лекарственной терапии 2010; 8 (1): 6–12 [Kuz’min OB, Zhezha VV, Landar’ LN. Nefroprotektivnye svojstva digidropipridinovyh blokatorov Ca2+kanalov. Obsory po klinicheskoj farmacologii i lekarstvennoj terapii 2010; 8 (1): 6–12]Uchida S, Takahashi M, Sugawara M, Saito T et al. Effects of the N/L-type calcium channel blocker cilnidihine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study). J Clin Hypertens (Greenwich) 2014; 16 (10): 746–753 doi: 10.1111/jch.12412Uchida S, Takahashi M, Sugawara M, Saito T et al. Effects of the N/L-type calcium channel blocker cilnidihine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study). J Clin Hypertens (Greenwich) 2014; 16 (10): 746–753 doi: 10.1111/jch.12412Takayama T, Yoda S, Yjima Y et al. Improvement of augmentation index and urinary albumin excretion with benedipine in hypertensive patients with chronic kidney disease. Int Heart J 2016; 57 (1): 53–60 doi: 10.1536/ihj.15-208Takayama T, Yoda S, Yjima Y et al. Improvement of augmentation index and urinary albumin excretion with benedipine in hypertensive patients with chronic kidney disease. Int Heart J 2016; 57 (1): 53–60 doi: 10.1536/ihj.15-208Breyer MD, Susztak K. Developing treatments for chronic kidney disease in the 21st century. Semin Nephrol 2016; 36 (6): 436–447 doi: 10.1016/j.semnephrol.2016.08.001Breyer MD, Susztak K. Developing treatments for chronic kidney disease in the 21st century. Semin Nephrol 2016; 36 (6): 436–447 doi: 10.1016/j.semnephrol.2016.08.001Benigni A, Perico N, Dadan J et al. Functional implications of decreased renal cortical atrial natriuretic peptide binding in experimental diabetes. Cirs Res 1990; 66 (6): 1453–1460Benigni A, Perico N, Dadan J et al. Functional implications of decreased renal cortical atrial natriuretic peptide binding in experimental diabetes. Cirs Res 1990; 66 (6): 1453–1460Polsin D, Kamincki HJ, Kastner C et al. Decreased renal corin expression contributes to sodium retention in proteinuric kidney diseases. Kidney Int 2010; 78 (7): 650–659 doi: 10.1038/ki.2010.197Polsin D, Kamincki HJ, Kastner C et al. Decreased renal corin expression contributes to sodium retention in proteinuric kidney diseases. Kidney Int 2010; 78 (7): 650–659 doi: 10.1038/ki.2010.197Abassi Z, Weissman I, Karram T et al. Restoration of renal responsiveness to atrial natriuretic peptide in experimental nephrotic syndrome by albumin infusion. Am J Nephrol 2013; 38 (4): 292–299 doi: 10.1159/000355014Abassi Z, Weissman I, Karram T et al. Restoration of renal responsiveness to atrial natriuretic peptide in experimental nephrotic syndrome by albumin infusion. Am J Nephrol 2013; 38 (4): 292–299 doi: 10.1159/000355014Zhao Y, Yu H, Zhao X et al. The effects of LCZ696 in patients with hypertension compared with angiotensin receptor blockers: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 2017; 22 (5): 447–457 doi: 10.1177/1074248417693379Zhao Y, Yu H, Zhao X et al. The effects of LCZ696 in patients with hypertension compared with angiotensin receptor blockers: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 2017; 22 (5): 447–457 doi: 10.1177/1074248417693379von Lueder TG, Wang BH, Kompa AR et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail 2015; 8 (1):71–88 doi: 10.1161/CIRCHEARTFAILURE.114.001785von Lueder TG, Wang BH, Kompa AR et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail 2015; 8 (1):71–88 doi: 10.1161/CIRCHEARTFAILURE.114.001785Voors AA, Cori M, Liu LC et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserve ejection fraction. Eur J Heart Fail 2015;17 (5): 510–517 doi: 10.1002/ejhf.232Voors AA, Cori M, Liu LC et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserve ejection fraction. Eur J Heart Fail 2015;17 (5): 510–517 doi: 10.1002/ejhf.2322016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure association (HFA) of the ESC. Eur J Heart Fail 2016;18 (8): 891–975 doi: 10.1002/ejhf.5922016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure association (HFA) of the ESC. Eur J Heart Fail 2016;18 (8): 891–975 doi: 10.1002/ejhf.592Kerkela R, Ulvila J, Magga J. Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events. J Am Heart Assoc 2015; 4: e002423 doi: 10.1161/JAHA.115.002423Kerkela R, Ulvila J, Magga J. Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events. J Am Heart Assoc 2015; 4: e002423 doi: 10.1161/JAHA.115.002423Meems LMG, Burnet JC. Innovative therapeutics: designer natriuretic peptides. JACC Basic Transl Sci. 2016; 1 (7): 557–567 doi: 10.1016/j.jacbts.2016.10.01Meems LMG, Burnet JC. Innovative therapeutics: designer natriuretic peptides. JACC Basic Transl Sci. 2016; 1 (7): 557–567 doi: 10.1016/j.jacbts.2016.10.01Hirsch JR, Meyer M, Forssmann WG. ANP and urodilatin: who is who in the kidney. Eur J Med Res 2006; 11 (10): 447–454Hirsch JR, Meyer M, Forssmann WG. ANP and urodilatin: who is who in the kidney. Eur J Med Res 2006; 11 (10): 447–454Wu Q, Xu-Cai YO, Chen S, Wang W. Corin: a new insights into natriuretic peptide system. Kidney Int 2009; 75 (2): 142–146 doi: 10.1038/ki.2008.418Wu Q, Xu-Cai YO, Chen S, Wang W. Corin: a new insights into natriuretic peptide system. Kidney Int 2009; 75 (2): 142–146 doi: 10.1038/ki.2008.418Wu C, Wu F, Pan J et al. Furin-mediated processing of pro-C-type natriuretic peptide. J Biol Chem 2003; 278 (28): 25847–25852Wu C, Wu F, Pan J et al. Furin-mediated processing of pro-C-type natriuretic peptide. J Biol Chem 2003; 278 (28): 25847–25852Theilig F, Wu Q. ANP-induced signaling cascade and its implications in renal pathophysiology. Am J Physiol Renal Physiol 2015; 308 (10); F1047–F1055 doi: 10.1152/ajprenal.00164.2014Theilig F, Wu Q. ANP-induced signaling cascade and its implications in renal pathophysiology. Am J Physiol Renal Physiol 2015; 308 (10); F1047–F1055 doi: 10.1152/ajprenal.00164.2014von Lueder TG, Sanralingham SJ, Wang BH et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail 2013; 6 (3): 594–605 doi: 10.1161/CIRCHEARTFAILURE.112.000289von Lueder TG, Sanralingham SJ, Wang BH et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail 2013; 6 (3): 594–605 doi: 10.1161/CIRCHEARTFAILURE.112.000289Kuhn M. Molecular physiology of membrane guanylyl cyclase receptors. Physiol Reviews 2016; 96 (2): 751–804 doi: 10.1152/physrev.00022.2015Kuhn M. Molecular physiology of membrane guanylyl cyclase receptors. Physiol Reviews 2016; 96 (2): 751–804 doi: 10.1152/physrev.00022.2015Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol 2014; 176 (3): 630–639 doi: 10.1016/j.ijcard.2014.08.032Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol 2014; 176 (3): 630–639 doi: 10.1016/j.ijcard.2014.08.032Li Y, Sarkar O, Brochu M, Anand-Srivastava MD. Natriuretic peptide receptor-C attenuates hypertension in spontaneously hypertensive rats: role nitroxidative stress and Gi proteins. Hypertension 2014; 63 (4): 8460855 doi: 10.1161/HYPERTENSIONAHA.113.01772Li Y, Sarkar O, Brochu M, Anand-Srivastava MD. Natriuretic peptide receptor-C attenuates hypertension in spontaneously hypertensive rats: role nitroxidative stress and Gi proteins. Hypertension 2014; 63 (4): 8460855 doi: 10.1161/HYPERTENSIONAHA.113.01772Rubattu S, Sciarretta S, Morriello A et. NHR-C: a component of natriuretic peptide family with implications in human diseases. J Mol Med (Berl) 2010; 88 (9): 889–897 doi: 10.1007/s00109-010-0641-2Rubattu S, Sciarretta S, Morriello A et. NHR-C: a component of natriuretic peptide family with implications in human diseases. J Mol Med (Berl) 2010; 88 (9): 889–897 doi: 10.1007/s00109-010-0641-2Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J 2011; 278 (11):1808–1817 doi: 10.1111/j.1742-4658.2011.08082.xPotter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J 2011; 278 (11):1808–1817 doi: 10.1111/j.1742-4658.2011.08082.xDomenig O, Manzel A, Grobe N et al. Neprilysin is a mediator of alternative renin-angiotensin system activation in the murine and human kidney. Sci Rep 2016; 6: 33678 doi: 10.1038/srep33678Domenig O, Manzel A, Grobe N et al. Neprilysin is a mediator of alternative renin-angiotensin system activation in the murine and human kidney. Sci Rep 2016; 6: 33678 doi: 10.1038/srep33678Dong L, Wang H, Dong N et al. Localization corin and atrial natriuretic peptide expression in human renal segments. Clin Sci London 2016; 130 (18): 1655–1664 doi: 10.1042/CS20160398Dong L, Wang H, Dong N et al. Localization corin and atrial natriuretic peptide expression in human renal segments. Clin Sci London 2016; 130 (18): 1655–1664 doi: 10.1042/CS20160398Ogawa Y, Mukoyama M, Yokoi H et al. Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J Am Soc Nephrol 2012; 23 (7): 1198–1209 doi: 10.1681/ASN.2011100985Ogawa Y, Mukoyama M, Yokoi H et al. Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J Am Soc Nephrol 2012; 23 (7): 1198–1209 doi: 10.1681/ASN.2011100985Wang W, Shen J, Cui Y et al. Impaired sodium excretion and salt sensitive hypertension in corin-deficient mice. Kidney Int 2012; 82 (1): 26–33 doi: 10.1038/ki.2012.41Wang W, Shen J, Cui Y et al. Impaired sodium excretion and salt sensitive hypertension in corin-deficient mice. Kidney Int 2012; 82 (1): 26–33 doi: 10.1038/ki.2012.41Nishikimi T, Inaba-Iemura C, Ichimura K et al. Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. Regul Pep 2009; 154 (1–3): 44–53 doi: 10.1016/j.regpep.2009.02.006Nishikimi T, Inaba-Iemura C, Ichimura K et al. Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. Regul Pep 2009; 154 (1–3): 44–53 doi: 10.1016/j.regpep.2009.02.006Yoshihara F, Tukodome T, Kishimoto I et al. Aggravated renal tubular damage and interstitial fibrosis in mice lacking guanylyl cyclase-A (GC-A), a receptor for atrial and B-type natriuretic peptides. Clin Exp Nephrol 2015; 19 (2): 197–207 doi: 10.1007/s10157-014-0982-1Yoshihara F, Tukodome T, Kishimoto I et al. Aggravated renal tubular damage and interstitial fibrosis in mice lacking guanylyl cyclase-A (GC-A), a receptor for atrial and B-type natriuretic peptides. Clin Exp Nephrol 2015; 19 (2): 197–207 doi: 10.1007/s10157-014-0982-1Staffel J, Valletta D, Federlein A et al. Natriuretic peptide receptor guanylyl cyclase-A in podocytes is renoprotective but dispensable for physiologic renal function. J Am Soc Nephrol 2017; 28 (1): 260–277 doi: 10.1681/ASN.2015070731Staffel J, Valletta D, Federlein A et al. Natriuretic peptide receptor guanylyl cyclase-A in podocytes is renoprotective but dispensable for physiologic renal function. J Am Soc Nephrol 2017; 28 (1): 260–277 doi: 10.1681/ASN.2015070731Kato Y, Mori K, Kasahara M et al. Natriuretic peptide receptor guanylyl cyclase-A pathway counteracts glomerular injury evoked by aldosterone through p38 mitogenactivated protein kinase inhibition. Sci Rep 2017; 7: 46624 doi: 10.1038/srep46624Kato Y, Mori K, Kasahara M et al. Natriuretic peptide receptor guanylyl cyclase-A pathway counteracts glomerular injury evoked by aldosterone through p38 mitogenactivated protein kinase inhibition. Sci Rep 2017; 7: 46624 doi: 10.1038/srep46624Terada Y, Tomita K, Nonoguchi H et al. PRC localization of C-type natriuretic peptide and B-type receptor mRNAs in rat nephron segments. Am J Physiol 1994; 267 (2): F215–F222Terada Y, Tomita K, Nonoguchi H et al. PRC localization of C-type natriuretic peptide and B-type receptor mRNAs in rat nephron segments. Am J Physiol 1994; 267 (2): F215–F222Osawa H, Yamabe H, Kaizuka M et al. C-type natriuretic peptide inhibits proliferation and monocyte chemoattractant protein-1 secretion in cultured human mesangial cells. Nephron 2000; 86 (4): 467–472 doi: 10.1159/000045836Osawa H, Yamabe H, Kaizuka M et al. C-type natriuretic peptide inhibits proliferation and monocyte chemoattractant protein-1 secretion in cultured human mesangial cells. Nephron 2000; 86 (4): 467–472 doi: 10.1159/000045836Lewko B, Endlich N, Kriz W et al. C-type natriuretic peptide as a podocyte hormone and modulation of its cGMP production by glucose and mechanical stress. Kidney Int 2004; 66 (3):1001–1008 doi: 10.1111/j.1523-1755.2004.00848.xLewko B, Endlich N, Kriz W et al. C-type natriuretic peptide as a podocyte hormone and modulation of its cGMP production by glucose and mechanical stress. Kidney Int 2004; 66 (3):1001–1008 doi: 10.1111/j.1523-1755.2004.00848.xGuo L-J, Alli AA, Eaton DC, Bao HF. ENaC is regulated by natriuretic peptide receptor-dependent cGMP signaling. Am J Physiol Renal Physiol 2013; 304 (7); F930–F937 doi: 10.1152/ajprenal.00638.2012Guo L-J, Alli AA, Eaton DC, Bao HF. ENaC is regulated by natriuretic peptide receptor-dependent cGMP signaling. Am J Physiol Renal Physiol 2013; 304 (7); F930–F937 doi: 10.1152/ajprenal.00638.2012Xu P, Wang J, Zhao XQ et al. Overexpressed C-type natriuretic peptide serves as an early compensatory response to counteract extracellular matrix remodeling in unilateral obstruction rats. Mol Biol Rep 2013; 40 (2): 1429–1441 doi: 10.1007/s11033-012-2186-7Xu P, Wang J, Zhao XQ et al. Overexpressed C-type natriuretic peptide serves as an early compensatory response to counteract extracellular matrix remodeling in unilateral obstruction rats. Mol Biol Rep 2013; 40 (2): 1429–1441 doi: 10.1007/s11033-012-2186-7Xu P, Zhang XC, Kong HB et al. Exogenous C-type natriuretic peptide infusion ameliorates unilateral ureteral obstructioninduced tubulointerstitial fibrosis in rats. Lab Invest 2015; 95 (3): 263–272 doi: 10.1038/labinvest.2014.149Xu P, Zhang XC, Kong HB et al. Exogenous C-type natriuretic peptide infusion ameliorates unilateral ureteral obstructioninduced tubulointerstitial fibrosis in rats. Lab Invest 2015; 95 (3): 263–272 doi: 10.1038/labinvest.2014.149Xu P, Xia X, Xuan Q et al. Neutral endopeptidase and natriuretic peptide receptors participate in the regulation of C-type natriuretic peptide expression in renal interstitial fibrosis. J Recept Signal Transduct Res 2017; 37 (1): 71–83 doi: 10.3109/10799893.2016.1155068Xu P, Xia X, Xuan Q et al. Neutral endopeptidase and natriuretic peptide receptors participate in the regulation of C-type natriuretic peptide expression in renal interstitial fibrosis. J Recept Signal Transduct Res 2017; 37 (1): 71–83 doi: 10.3109/10799893.2016.1155068Spanus KS, Kronenberg F, Ritz E et al. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild to Moderate Kidney Disease study. Clin Chem 2007; 53 (7): 1264–1267 doi: 10.1373/clinchem.2006.083170Spanus KS, Kronenberg F, Ritz E et al. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild to Moderate Kidney Disease study. Clin Chem 2007; 53 (7): 1264–1267 doi: 10.1373/clinchem.2006.083170Yoshitomi R, Nakayama M, Sakoh T et al. Plasma B-type natriuretic peptide concentration is independently associated with kidney function decline in Japanese patients. J Hypertens 2016; 34 (4): 753–761 doi: 10.1097/HJH.0000000000000847Yoshitomi R, Nakayama M, Sakoh T et al. Plasma B-type natriuretic peptide concentration is independently associated with kidney function decline in Japanese patients. J Hypertens 2016; 34 (4): 753–761 doi: 10.1097/HJH.0000000000000847Schaub JA, Coca SG, Moledina DG et al. Amino-terminal pro-B-type natriuretic peptide for diagnosis and prognosis in patients with renal dysfunction: a systematic review and metaanalysis. JASS Heart Fail 2015; 3 (12): 977–989 doi: 10.1016/j.jchf.2015.07.014Schaub JA, Coca SG, Moledina DG et al. Amino-terminal pro-B-type natriuretic peptide for diagnosis and prognosis in patients with renal dysfunction: a systematic review and metaanalysis. JASS Heart Fail 2015; 3 (12): 977–989 doi: 10.1016/j.jchf.2015.07.014Fang C, Shen L, Dong L et al. Reduced urinary corin levels in patients with chronic kidney disease. Clin Sci (London) 2013; 124 (12): 709–717 doi: 10.1042/CS20120517Fang C, Shen L, Dong L et al. Reduced urinary corin levels in patients with chronic kidney disease. Clin Sci (London) 2013; 124 (12): 709–717 doi: 10.1042/CS20120517Bae EH, Lee J, Ma SK, Kim SW. Changes of atrial natriuretic peptide system in rats with puromycin aminonucleoside-induced nephrotic syndrome. Korean J Physiol Pharmacol 2009; 13 (1): 1–7 doi: 10.4196/kjpp.2009.13.1.1Bae EH, Lee J, Ma SK, Kim SW. Changes of atrial natriuretic peptide system in rats with puromycin aminonucleoside-induced nephrotic syndrome. Korean J Physiol Pharmacol 2009; 13 (1): 1–7 doi: 10.4196/kjpp.2009.13.1.1Obineche EN, Adeghate E, Chandranath IS et al. Alterations in atrial natriuretic peptide and its receptors in streptozotocininduced diabetic rat kidneys. Mol Cell Biochem 2004; 261 (1): 3–8Obineche EN, Adeghate E, Chandranath IS et al. Alterations in atrial natriuretic peptide and its receptors in streptozotocininduced diabetic rat kidneys. Mol Cell Biochem 2004; 261 (1): 3–8Obineche EN, Chandranath IS, Adeghate E et al. Alterations in atrial natriuretic peptide and its receptor levels in long-term streptozotocin-induced diabetes in rats. Ann N Y Acad Sci 2006; 1084: 223–234 doi: 10.1196/annals.1372.025Obineche EN, Chandranath IS, Adeghate E et al. Alterations in atrial natriuretic peptide and its receptor levels in long-term streptozotocin-induced diabetes in rats. Ann N Y Acad Sci 2006; 1084: 223–234 doi: 10.1196/annals.1372.025Jespersen B, Eiskjaer H, Mogensen CE et al. Reduced natriuretic effect of atrial natriuretic peptide: a possible role of decreased cyclic guanosine monophospate. Nephron 1995; 71 (1): 44–53Jespersen B, Eiskjaer H, Mogensen CE et al. Reduced natriuretic effect of atrial natriuretic peptide: a possible role of decreased cyclic guanosine monophospate. Nephron 1995; 71 (1): 44–53Plum J, Mirzaian Y, Grabensee B. Atrial natriuretic peptide, sodium retention, and proteinuria in nephrotic syndrome. Nephrol Dial Transplant 1996; 11 (6): 1034–1042Plum J, Mirzaian Y, Grabensee B. Atrial natriuretic peptide, sodium retention, and proteinuria in nephrotic syndrome. Nephrol Dial Transplant 1996; 11 (6): 1034–1042Taal MW, Nenov VD, Wong W et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme alone. J Am Soc Nephrol 2001; 12 (10): 2051–2059Taal MW, Nenov VD, Wong W et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme alone. J Am Soc Nephrol 2001; 12 (10): 2051–2059Packer M, Califf RM, Konstam RA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure. The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106 (8): 920–926 doi: 10.1161/01.CIR.0000029801.86489.50Packer M, Califf RM, Konstam RA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure. The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106 (8): 920–926 doi: 10.1161/01.CIR.0000029801.86489.50Gu J, Noe A, Chandra P et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensinneprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50 (4): 401–414 doi: 10.1177/0091270009343932Gu J, Noe A, Chandra P et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensinneprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50 (4): 401–414 doi: 10.1177/0091270009343932Hegde LG, Yu C, Renner P et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol 2011; 57 (4): 495–504 doi: 10.1097/FJC.0b01e318210fc7eHegde LG, Yu C, Renner P et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol 2011; 57 (4): 495–504 doi: 10.1097/FJC.0b01e318210fc7eUshijima K, Ando Y, Arakawa Y et al. Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/ valsartan (LCZ696), a dual acting angiotensin receptor-neprilysin inhibitor. Pharmacol Res Perspect 2017; 5 (4): e00336 doi: 10.1002/prp2.336Ushijima K, Ando Y, Arakawa Y et al. Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/ valsartan (LCZ696), a dual acting angiotensin receptor-neprilysin inhibitor. Pharmacol Res Perspect 2017; 5 (4): e00336 doi: 10.1002/prp2.336Ito S, Satoh M, Tamaki Y et al. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res 2015; 38 (4): 269–275 doi: 10.1038/hr.2015.1Ito S, Satoh M, Tamaki Y et al. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res 2015; 38 (4): 269–275 doi: 10.1038/hr.2015.1Voors AA, Gori M, Liu LC et al. Renal effects of angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2015; 17 (5): 510–517 doi: 10.1002/ejhf.232Voors AA, Gori M, Liu LC et al. Renal effects of angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2015; 17 (5): 510–517 doi: 10.1002/ejhf.232Jacobs EM, Vervoort J, Branten AJ et al. Atrial natriuretic peptide increases albuminuria in type 1 diabetic patients: evidence for blockade of tubular protein reabsorption. Eur J Clin Invest 1999; 29 (2): 109–115 doi: 10.1046/j.1365–2362.1999.00422.xJacobs EM, Vervoort J, Branten AJ et al. Atrial natriuretic peptide increases albuminuria in type 1 diabetic patients: evidence for blockade of tubular protein reabsorption. Eur J Clin Invest 1999; 29 (2): 109–115 doi: 10.1046/j.1365–2362.1999.00422.xUK HARP-III Collaborative Group. Randomized multicentre pilot study of sacubitryl/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)-III rationale, trial design and baseline data. Nephrol Dial Transplant 2016; pii gfw321 doi: 10.1093/ndt/gfw321UK HARP-III Collaborative Group. Randomized multicentre pilot study of sacubitryl/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)-III rationale, trial design and baseline data. Nephrol Dial Transplant 2016; pii gfw321 doi: 10.1093/ndt/gfw321

The authors declare that there are no conflicts of interest present.